{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:13Z","timestamp":1789749493587,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jid.2024.10.602","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:17:51Z","timestamp":1731554271000},"page":"1396-1406.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7031-2710","authenticated-orcid":false,"given":"Akshay","family":"Flora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-3889","authenticated-orcid":false,"given":"James","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7459-2702","authenticated-orcid":false,"given":"Jane A.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-5479","authenticated-orcid":false,"given":"Michael","family":"Radzeika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-2977","authenticated-orcid":false,"given":"Hugh","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-8841","authenticated-orcid":false,"given":"Mathew","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-3632","authenticated-orcid":false,"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.10.602_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2018.1438269","article-title":"Pyoderma gangrenosum: a review of pathogenesis and treatment","volume":"14","author":"Ahn","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jid.2024.10.602_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment","volume":"18","author":"Alavi","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.20748","article-title":"Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn\u2019s disease","volume":"15","author":"Alkhouri","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jid.2024.10.602_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdcr.2020.12.005","article-title":"Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum","volume":"8","author":"Baier","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.10.602_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2016.05.044","article-title":"Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: the Mayo Clinic experience, 1996 through 2013","volume":"75","author":"Barbosa","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa163","article-title":"An approach for normalization and quality control for Nanostring RNA expression data","volume":"22","author":"Bhattacharya","year":"2021","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.jid.2024.10.602_bib7","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3465","article-title":"Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol","volume":"9","author":"Crowe","year":"2019","journal-title":"Bio Protoc"},{"key":"10.1016\/j.jid.2024.10.602_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib9","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1111\/jdv.18543","article-title":"Angiotensin-converting enzyme 2 expression is elevated in tissue of hidradenitis suppurativa and pyoderma gangrenousm and demonstrates a different pattern of expression to psoriasis vulgaris","volume":"37","author":"Flora","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.10.602_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jid.2023.10.005","article-title":"Alterations to the hidradenitis suppurativa serum proteome with spleen tyrosine kinase antagonism: proteomic results from a phase 2 clinical trial","volume":"144","author":"Flora","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/exd.14534","article-title":"Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease","volume":"31","author":"Flora","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib12","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1111\/jdv.19611","article-title":"The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa","volume":"38","author":"Flora","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.10.602_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4939-9904-0_10","article-title":"Nanostring nCounter technology: high-throughput RNA validation","volume":"2079","author":"Goytain","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jid.2024.10.602_bib15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2147\/CCID.S374534","article-title":"Recalcitrant ulcerative pyoderma gangrenosum of the leg responsive to tildrakizumab: a case report","volume":"15","author":"Leow","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2015.07.023","article-title":"Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis","volume":"242","author":"Lind","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jid.2024.10.602_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjd.19027","article-title":"Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review","volume":"183","author":"Lu","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cei.12394","article-title":"Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome","volume":"178","author":"Marzano","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2024.10.602_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/09546634.2018.1506083","article-title":"Biologic and small-molecule medications in the management of pyoderma gangrenosum","volume":"30","author":"McKenzie","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.10.602_bib21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.10.602_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaad.2021.07.035","article-title":"The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris","volume":"86","author":"Navrazhina","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib23","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/ced.15183","article-title":"Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review","volume":"47","author":"Orita","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2024.10.602_bib25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jid.2021.08.431","article-title":"Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression","volume":"142","author":"Ortega-Loayza","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.10.602_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jid.2024.10.602_bib28","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3389\/fimmu.2017.01980","article-title":"Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24028926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24028926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:40:21Z","timestamp":1780278021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24028926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022202X24028926"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.10.602","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.10.602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}